Background Alzheimer's disease (AD) is a heterogeneous, multifactorial neurodegenerative
disorder characterized by three neurobiological factors beta‐amyloid, pathologic tau, and …

Alzheimer's disease (AD) is clinically heterogeneous in presentation and progression,
demonstrating variable topographic distributions of clinical phenotypes, progression rate …

Alzheimer's disease (AD) is a degenerative brain disease impairing a person's ability to
perform day to day activities. The clinical manifestations of Alzheimer's disease are …

Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, yet its current
treatments are limited to stopping disease progression. Moreover, the effectiveness of these …

Alzheimer's disease (AD) is a heterogeneous, multifactorial neurodegenerative disorder,
where beta-amyloid (A), pathologic tau (T), neurodegeneration ([N]), and structural brain …

In a recent article from Cell Reports Medicine, Kwak et al. generate novel insights about
subtyping cognitively impaired individuals based on structural imaging. Quantifying …

The heterogeneity of neurodegenerative diseases is a key confound to disease
understanding and treatment development, as study cohorts typically include multiple …

The pathogenesis of Alzheimer's disease (AD) remains unclear, but revealing individual
differences in functional connectivity (FC) may provide insights and improve diagnostic …

The heterogeneity of Alzheimer's disease (AD) poses a challenge to precision medicine. We
aimed to identify distinct subtypes of AD based on the individualized structural covariance …

Quantifying heterogeneity in Alzheimer's disease (AD) risk is critical for individualized care
and management. Recent attempts to assess AD heterogeneity have used structural …